| Preview | Issue Date | Title / Name | Author(s) | Type |
| 2022 | CDK4/6 Inhibitors (CKD4/6i) in advanced hormone-receptor-positive (HR+) HER2-negative (HER2-) breast cancer: Prescribing practices and outcomes in a real-world, Australian cohort | Javaid, Anadil; Lok, Sheau Wen; Wong, Vanessa; Baron-Hay, Sally; Boyle, Fran, et al | Conference Paper | |
 | Jun-2022 | DNA sequencing and gene-expression profiling assists in making a tissue of origin diagnosis in cancer of unknown primary | Posner, A.; Prall, Owen W. J.; Sivakumaran, Tharani; Etemadamoghadam, D.; Thio, N., et al | Journal Article | |
| 2018 | Management of brainmetastases in patients with HER2 positive breast cancer-a real world Australian experience | Moldovan, Cristina A.; King, Rossa; Lok, Sheau Wen; De Boer, Richard; Gibbs, Peter, et al | Conference Paper | |
| 2019 | Management of neuroendocrine tumours in metropolitan and regional South West Victoria | Dean, Samantha L.; Hayes, Theresa M.; Rogers, Margaret J.; Versace, Vincent; Collins, Ian M., et al | Conference Paper | |
| 2021 | MO01.39 Liposomal Irinotecan in Adults with Small Cell Lung Cancer who Progressed on Platinum-Based Therapy: Subgroup Analyses by Platinum Sensitivity | Spigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2019 | OA03.03 Initial Efficacy and Safety Results of Irinotecan Liposome Injection (nal-IRI) in Patients with Small Cell Lung Cancer | Paz-Ares Rodriguez, L.; Spigel, David R.; Chen, Yuanbin; Jove, Maria; Juan, O., et al | Conference Paper | |
| 2021 | P48.14 RESILIENT Part 2: A phase 3 Study of Liposomal Irinotecan in Patients with Small-Cell Lung Cancer in the Second-Line Setting | Paz-Ares, Luis; Spigel, David R.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2019 | Prostate cancer outcome disparity in South West Victoria | Dean, Samantha L.; Matheson, Leigh M.; Davidson, Adee J.; Grills, Richard; Kearns, Paul, et al | Conference Paper | |
| 2020 | Real world outcomes in elderly patients with HER2 positive advanced breast cancer | Evans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard, et al | Conference Paper | |
| 2021 | Real world outcomes in elderly women with HER2 positive advanced breast cancer | Evans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard, et al | Conference Paper | |
 | 2020 | Real World Outcomes in Elderly Women with HER2-Positive Advanced Breast Cancer | Evans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard, et al | Conference Paper | |
| 2021 | Real-world outcomes in patients with brain metastases secondary to HER2-positive breast cancer: An Australian multi-centre registry-based study | Tung, Iris; Moldovan, Cristina; Wong, Vanessa; De Boer, Richard; Gibbs, Peter, et al | Conference Paper | |
| 2020 | RESILIENT part I, an open-label, safety run-in of liposomal irinotecan in adults with small cell lung cancer (SCLC) who have progressed with platinum-based first-line (1L) therapy: Subgroup analyses by platinum sensitivity | Spigel, David R.; Paz-Ares, Luis G.; Chen, Yuanbin; Jove, Maria; Juan-Vidal, Oscar, et al | Conference Paper | |
| 2020 | RESILIENT part II: An open-label, randomized, phase III study of liposomal irinotecan injection in patients with small-cell lung cancer who have progressed with platinum-based first-line therapy | Spigel, David R.; Paz-Ares, Luis G.; Moore, Yan; Zhang, Bin; Dowlati, Afshin, et al | Conference Paper | |
